Join
Live feed
·
PRReleasevia Quantisnow
BioLineRx Ltd. logo

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model

ByQuantisnow·Wall Street's wire, on your screen.
BLRX· BioLineRx Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BLRX (BioLineRx Ltd.) and more on Quantisnow.